Arca Biopharma Stock Probability of Future Stock Price Finishing Over 2.02

ABIO Stock  USD 3.25  0.04  1.25%   
ARCA Biopharma's implied volatility is one of the determining factors in the pricing options written on ARCA Biopharma. Implied volatility approximates the future value of ARCA Biopharma based on the option's current value. Options with high implied volatility have higher premiums and can be used to hedge the downside of investing in ARCA Biopharma over a specific time period. For example, 2024-04-19 CALL at $2.5 is a CALL option contract on ARCA Biopharma's common stock with a strick price of 2.5 expiring on 2024-04-19. The contract was last traded on 2024-04-18 at 15:39:20 for $0.4 and, as of today, has 0 days remaining before the expiration. The option is currently trading at a bid price of $0.0, and an ask price of $0.85. The implied volatility as of the 19th of April is 602.99. View All ARCA options

Closest to current price ARCA long CALL Option Payoff at Expiration

ARCA Biopharma's future price is the expected price of ARCA Biopharma instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of ARCA Biopharma performance during a given time horizon utilizing its historical volatility. Check out ARCA Biopharma Backtesting, ARCA Biopharma Valuation, ARCA Biopharma Correlation, ARCA Biopharma Hype Analysis, ARCA Biopharma Volatility, ARCA Biopharma History as well as ARCA Biopharma Performance.
To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.
  
As of the 19th of April 2024, Price To Sales Ratio is likely to drop to 0.26. In addition to that, Price Earnings Ratio is likely to drop to -4.82. Please specify ARCA Biopharma's target price for which you would like ARCA Biopharma odds to be computed.

ARCA Biopharma Target Price Odds to finish over 2.02

The tendency of ARCA Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above $ 2.02  in 90 days
 3.25 90 days 2.02 
about 44.61
Based on a normal probability distribution, the odds of ARCA Biopharma to stay above $ 2.02  in 90 days from now is about 44.61 (This ARCA Biopharma probability density function shows the probability of ARCA Stock to fall within a particular range of prices over 90 days) . Probability of ARCA Biopharma price to stay between $ 2.02  and its current price of $3.25 at the end of the 90-day period is about 43.29 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.55 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, ARCA Biopharma will likely underperform. Moreover ARCA Biopharma has an alpha of 1.3714, implying that it can generate a 1.37 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
   ARCA Biopharma Price Density   
       Price  

Predictive Modules for ARCA Biopharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ARCA Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ARCA Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.163.2814.77
Details
Intrinsic
Valuation
LowRealHigh
0.173.3614.85
Details
Naive
Forecast
LowNextHigh
0.063.1214.60
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as ARCA Biopharma. Your research has to be compared to or analyzed against ARCA Biopharma's peers to derive any actionable benefits. When done correctly, ARCA Biopharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in ARCA Biopharma.

ARCA Biopharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. ARCA Biopharma is not an exception. The market had few large corrections towards the ARCA Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ARCA Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ARCA Biopharma within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
1.37
β
Beta against NYSE Composite1.55
σ
Overall volatility
0.59
Ir
Information ratio 0.13

ARCA Biopharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ARCA Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ARCA Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
ARCA Biopharma is way too risky over 90 days horizon
ARCA Biopharma appears to be risky and price may revert if volatility continues
Net Loss for the year was (5.34 M) with profit before overhead, payroll, taxes, and interest of 0.
ARCA Biopharma currently holds about 46.44 M in cash with (5.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22.
ARCA Biopharma has a poor financial position based on the latest SEC disclosures
Roughly 72.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: ARCA biopharma, Inc. Short Interest Up 6.6 percent in March - Defense World

ARCA Biopharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ARCA Stock often depends not only on the future outlook of the current and potential ARCA Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ARCA Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding14.4 M
Cash And Short Term Investments37.4 M

ARCA Biopharma Technical Analysis

ARCA Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. ARCA Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of ARCA Biopharma. In general, you should focus on analyzing ARCA Stock price patterns and their correlations with different microeconomic environments and drivers.

ARCA Biopharma Predictive Forecast Models

ARCA Biopharma's time-series forecasting models is one of many ARCA Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary ARCA Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about ARCA Biopharma

Checking the ongoing alerts about ARCA Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for ARCA Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
ARCA Biopharma is way too risky over 90 days horizon
ARCA Biopharma appears to be risky and price may revert if volatility continues
Net Loss for the year was (5.34 M) with profit before overhead, payroll, taxes, and interest of 0.
ARCA Biopharma currently holds about 46.44 M in cash with (5.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22.
ARCA Biopharma has a poor financial position based on the latest SEC disclosures
Roughly 72.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: ARCA biopharma, Inc. Short Interest Up 6.6 percent in March - Defense World
When determining whether ARCA Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ARCA Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arca Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arca Biopharma Stock:

Complementary Tools for ARCA Stock analysis

When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.37)
Return On Assets
(0.11)
Return On Equity
(0.14)
The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.